Compare GRWG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | IVA |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 1.1B |
| IPO Year | 2015 | 2020 |
| Metric | GRWG | IVA |
|---|---|---|
| Price | $1.84 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $2.50 | ★ $16.20 |
| AVG Volume (30 Days) | 405.6K | ★ 741.6K |
| Earning Date | 05-08-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $1.01 | $3.35 |
| 52 Week High | $2.40 | $7.98 |
| Indicator | GRWG | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 74.92 | 54.53 |
| Support Level | $1.32 | $4.48 |
| Resistance Level | $2.40 | $4.70 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 90.68 | 57.64 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.